Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Chief Accounting Officer | March 17, 2020 | March 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 17, 2020 · Filed March 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2020-03-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-03-17 · Exercise / conversion · Acquired 944 · Balance 944 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 2 · 2020-03-17 · Sale · Disposed 944 · Balance 0 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-03-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-17 · Exercise / conversion · Disposed 944 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4: Restricted share units were granted on March 17, 2016, with 943 vesting on each of March 17, 2018 and March 17, 2019 and 944 vesting on March 17, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Restricted share units were granted on March 17, 2016, with 943 vesting on each of March 17, 2018 and March 17, 2019 and 944 vesting on March 17, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2020 Filed Mar 19, 2020 12:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020167 · doc4.xml · derivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 944 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 943 vesting on each of March 17, 2018 and March 17, 2019 and 944 vesting on March 17, 2020. F4 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 943 vesting on each of March 17, 2018 and March 17, 2019 and 944 vesting on March 17, 2020. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 12:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 944 | $7.16 | $6,762.34 |
DisclosureSEC source: 0001209191-20-020167 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 12:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-020167 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 13:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 4,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016462 · doc4.xml · derivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,424 Underlying: Ordinary Shares · 4,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 4,807 vesting on each of March 4, 2020, March 4, 2021 and March 4, 2022 and 4,810 vesting on March 4, 2023. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 4,807 vesting on each of March 4, 2020, March 4, 2021 and March 4, 2022 and 4,810 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 13:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,807 | $11.23 | $53,979.73 |
DisclosureSEC source: 0001209191-20-016462 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.0900 to $11.3800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 13:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016462 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 11:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015874 · doc4.xml · derivative · entry 6 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,166 Underlying: Ordinary Shares · 1,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 11:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,166 | $11.37 | $13,252.52 |
DisclosureSEC source: 0001209191-20-015874 · doc4.xml · nonDerivative · entry 4 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.8900 to $11.7400, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 11:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-015874 · doc4.xml · nonDerivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 11:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015874 · doc4.xml · derivative · entry 5 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,882 Underlying: Ordinary Shares · 2,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 2, 2018, with 2,941 vesting on each of March 2, 2019, March 2, 2020, March 2, 2021 and March 2, 2022. F5 · derivative.expiration_date: Restricted share units were granted on March 2, 2018, with 2,941 vesting on each of March 2, 2019, March 2, 2020, March 2, 2021 and March 2, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 11:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,941 | $11.60 | $34,112.36 |
DisclosureSEC source: 0001209191-20-015874 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.4600 to $11.7300, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 11:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-015874 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 12:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 21,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014850 · doc4.xml · derivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,459 Underlying: Ordinary Shares · 21,459 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 5,364 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 5,367 vesting on February 28, 2024. F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 5,364 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 5,367 vesting on February 28, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050263 · doc4.xml · derivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,376 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 2,376 vesting on each of September 18, 2018 and September 18, 2019. F4 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 2,376 vesting on each of September 18, 2018 and September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,376 | $7.83 | $18,607.17 |
DisclosureSEC source: 0001209191-19-050263 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.82 to $7.835, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,376 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-050263 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 12:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 943 | $16.63 | $15,677.47 |
DisclosureSEC source: 0001209191-19-020158 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 943 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020158 · doc4.xml · derivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 944 Underlying: Ordinary Shares · 943 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 943 vesting on each of March 17, 2018 and March 17, 2019 and 944 vesting on March 17, 2020. F4 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 943 vesting on each of March 17, 2018 and March 17, 2019 and 944 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 943 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-020158 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 953 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019328 · doc4.xml · derivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 953 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 952 vesting on March 12, 2018 and 953 vesting on March 12, 2019. F4 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 952 vesting on March 12, 2018 and 953 vesting on March 12, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 953 | $15.67 | $14,938.18 |
DisclosureSEC source: 0001209191-19-019328 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.6600 to $15.6911, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-019328 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,166 | $16.88 | $19,685.93 |
DisclosureSEC source: 0001209191-19-016087 · doc4.xml · nonDerivative · entry 4 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.130, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,941 | $16.88 | $49,653.79 |
DisclosureSEC source: 0001209191-19-016087 · doc4.xml · nonDerivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,166 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.130, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 12:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 19,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017231 · doc4.xml · derivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,321 Underlying: Ordinary Shares · 19,321 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 4,807 vesting on March 4, 2020 and 4,808 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 4,807 vesting on March 4, 2020 and 4,808 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016087 · doc4.xml · derivative · entry 5 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,332 Underlying: Ordinary Shares · 1,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F4 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-016087 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016087 · doc4.xml · derivative · entry 6 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,823 Underlying: Ordinary Shares · 2,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 2, 2018, with 2,941 vesting on each of March 2, 2019, March 2, 2020, March 2, 2021 and March 2, 2022. F5 · derivative.expiration_date: Restricted share units were granted on March 2, 2018, with 2,941 vesting on each of March 2, 2019, March 2, 2020, March 2, 2021 and March 2, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-016087 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051775 · doc4.xml · derivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,376 Underlying: Ordinary Shares · 2,376 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 2,376 vesting on each of September 18, 2018 and September 18, 2019. F4 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 2,376 vesting on each of September 18, 2018 and September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,376 | $23.71 | $56,327.83 |
DisclosureSEC source: 0001209191-18-051775 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.640 to $23.735, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,376 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-051775 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 943 | $17.88 | $16,858.95 |
DisclosureSEC source: 0001209191-18-020860 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.83 to $17.925, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 943 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020860 · doc4.xml · derivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,887 Underlying: Ordinary Shares · 943 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 943 vesting on each of March 17, 2018 and March 17, 2019 and 944 vesting on March 17, 2020. F4 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 943 vesting on each of March 17, 2018 and March 17, 2019 and 944 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 943 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-020860 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 952 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019563 · doc4.xml · derivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953 Underlying: Ordinary Shares · 952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 952 vesting on March 12, 2018 and 953 vesting on March 12, 2019. F4 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 952 vesting on March 12, 2018 and 953 vesting on March 12, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 952 | $19.49 | $18,553.53 |
DisclosureSEC source: 0001209191-18-019563 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.46 to $19.50, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:29 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 952 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-019563 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 773 | $19.38 | $14,980.74 |
DisclosureSEC source: 0001209191-18-017210 · doc4.xml · nonDerivative · entry 3 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Tax withholdingOrdinary Shares | 393 | $19.38 | $7,616.34 |
DisclosureSEC source: 0001209191-18-017210 · doc4.xml · nonDerivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 773 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017210 · doc4.xml · derivative · entry 4 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,498 Underlying: Ordinary Shares · 1,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017210 · doc4.xml · nonDerivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 02, 2018 Filed Oct 9, 2018 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 11,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054504 · doc4.xml · derivative · entry 2 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,764 Underlying: Ordinary Shares · 11,764 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 2, 2018, with 2,941 vesting on each of March 2, 2019, March 2, 2020, March 2, 2021 and March 2, 2022. F4 · derivative.expiration_date: Restricted share units were granted on March 2, 2018, with 2,941 vesting on each of March 2, 2019, March 2, 2020, March 2, 2021 and March 2, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 02, 2018 Filed Oct 9, 2018 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantStock Options (right to buy) · Derivative | 30,002 | $0.00 Strike: $19.16 | $0.00 |
DisclosureSEC source: 0001209191-18-054504 · doc4.xml · derivative · entry 1 Griffin Deborah A · CIK 0001719115 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,002 Underlying: Ordinary Shares · 30,002 shares Expires 2028-03-02 F1 · derivative.exercise_date: Stock options were granted on March 2, 2018, with 7,500 vesting on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 7,502 vesting on March 2, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.